Neoleukin Therapeutics, Inc.
Neoleukin Therapeutics, Inc. (NLTX) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nltx · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Neoleukin Therapeutics, Inc. (NLTX) measures how much investors pay for each dollar of the company's trailing earnings. NLTX's current PE ratio of N/A is calculated by dividing its stock price of $3.49 by its TTM earnings per share of -$4.42.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2012 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Neoleukin Therapeutics, Inc.You NLTX | $8M | N/A | — | -$4.42 |
 Biora Therapeutics, Inc. BIOR | $1M | N/A | — | -$78.69 |
 Channel Therapeutics Corporation CHRO | $9M | N/A | — | -$2.30 |
 Centogene N.V. CNTG | $9M | N/A | — | -$1.26 |
 COSCIENS Biopharma Inc. CSCI | $9M | N/A | — | -$5.93 |
 DMK Pharmaceuticals Corporation DMKPQ | $0M | N/A | — | -$12.37 |
 Lannett Company, Inc. LCI | $7M | N/A | — | -$22.96 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $0.00 | — | |
2024-12-31 FY2024 | — | $-3.96 | — | |
2022-12-31 FY2022 | — | $-5.21 | — | |
2021-12-31 FY2021 | — | $-5.51 | — | |
2020-12-31 FY2020 | — | $-3.21 | — | |
2019-12-31 FY2019 | — | $-12.85 | — | |
2018-12-31 FY2018 | — | $-6.71 | — | |
2017-12-31 FY2017 | — | $-10.70 | — | |
2016-12-31 FY2016 | — | $-9.79 | — | |
2015-12-31 FY2015 | — | $-8.65 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Neoleukin Therapeutics, Inc. (NLTX) measures how much investors pay for each dollar of the company's trailing earnings. NLTX's current PE ratio of N/A is calculated by dividing its stock price of $3.49 by its TTM earnings per share of -$4.42.
Frequently asked questions
NLTX pe ratio · 6 questionsNLTX's current PE ratio is N/A as of 2026-06-09, based on a stock price of $3.49 and TTM EPS of -$4.42. Data sourced from Financial Modeling Prep via NLTX's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Neoleukin Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09